Your browser doesn't support javascript.
loading
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.
King, Lloyd D W; Pulido, David; Barrett, Jordan R; Davies, Hannah; Quinkert, Doris; Lias, Amelia M; Silk, Sarah E; Pattinson, David J; Diouf, Ababacar; Williams, Barnabas G; McHugh, Kirsty; Rodrigues, Ana; Rigby, Cassandra A; Strazza, Veronica; Suurbaar, Jonathan; Rees-Spear, Chloe; Dabbs, Rebecca A; Ishizuka, Andrew S; Zhou, Yu; Gupta, Gaurav; Jin, Jing; Li, Yuanyuan; Carnrot, Cecilia; Minassian, Angela M; Campeotto, Ivan; Fleishman, Sarel J; Noe, Amy R; MacGill, Randall S; King, C Richter; Birkett, Ashley J; Soisson, Lorraine A; Long, Carole A; Miura, Kazutoyo; Ashfield, Rebecca; Skinner, Katherine; Howarth, Mark R; Biswas, Sumi; Draper, Simon J.
Afiliação
  • King LDW; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK; Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, OX1 3QU Oxford, UK; The Jenner Institute, University of Oxford, Old Road Campus Research Buildi
  • Pulido D; The Jenner Institute, University of Oxford, Old Road Campus Research Building, OX3 7DQ Oxford, UK.
  • Barrett JR; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK; Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, OX1 3QU Oxford, UK; The Jenner Institute, University of Oxford, Old Road Campus Research Buildi
  • Davies H; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK; Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, OX1 3QU Oxford, UK; The Jenner Institute, University of Oxford, Old Road Campus Research Buildi
  • Quinkert D; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK; Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, OX1 3QU Oxford, UK; The Jenner Institute, University of Oxford, Old Road Campus Research Buildi
  • Lias AM; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK; Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, OX1 3QU Oxford, UK; The Jenner Institute, University of Oxford, Old Road Campus Research Buildi
  • Silk SE; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK; Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, OX1 3QU Oxford, UK; The Jenner Institute, University of Oxford, Old Road Campus Research Buildi
  • Pattinson DJ; The Jenner Institute, University of Oxford, Old Road Campus Research Building, OX3 7DQ Oxford, UK.
  • Diouf A; Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.
  • Williams BG; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK; Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, OX1 3QU Oxford, UK; The Jenner Institute, University of Oxford, Old Road Campus Research Buildi
  • McHugh K; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK; Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, OX1 3QU Oxford, UK; The Jenner Institute, University of Oxford, Old Road Campus Research Buildi
  • Rodrigues A; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK; Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, OX1 3QU Oxford, UK.
  • Rigby CA; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK; Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, OX1 3QU Oxford, UK.
  • Strazza V; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK; Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, OX1 3QU Oxford, UK.
  • Suurbaar J; The Jenner Institute, University of Oxford, Old Road Campus Research Building, OX3 7DQ Oxford, UK; West African Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra LG 54, Ghana.
  • Rees-Spear C; The Jenner Institute, University of Oxford, Old Road Campus Research Building, OX3 7DQ Oxford, UK; London School of Hygiene and Tropical Medicine, WC1E 7HT London, UK.
  • Dabbs RA; The Jenner Institute, University of Oxford, Old Road Campus Research Building, OX3 7DQ Oxford, UK.
  • Ishizuka AS; The Jenner Institute, University of Oxford, Old Road Campus Research Building, OX3 7DQ Oxford, UK.
  • Zhou Y; The Jenner Institute, University of Oxford, Old Road Campus Research Building, OX3 7DQ Oxford, UK.
  • Gupta G; The Jenner Institute, University of Oxford, Old Road Campus Research Building, OX3 7DQ Oxford, UK.
  • Jin J; The Jenner Institute, University of Oxford, Old Road Campus Research Building, OX3 7DQ Oxford, UK.
  • Li Y; The Jenner Institute, University of Oxford, Old Road Campus Research Building, OX3 7DQ Oxford, UK.
  • Carnrot C; Novavax AB, Kungsgatan 109, 753 18 Uppsala, Sweden.
  • Minassian AM; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK; Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, OX1 3QU Oxford, UK; The Jenner Institute, University of Oxford, Old Road Campus Research Buildi
  • Campeotto I; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK.
  • Fleishman SJ; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Noe AR; Leidos Life Sciences, Frederick, MD, USA.
  • MacGill RS; Center for Vaccine Innovation and Access, PATH, Washington, DC 20001, USA.
  • King CR; Center for Vaccine Innovation and Access, PATH, Washington, DC 20001, USA.
  • Birkett AJ; Center for Vaccine Innovation and Access, PATH, Washington, DC 20001, USA.
  • Soisson LA; USAID, 1300 Pennsylvania Avenue NW, Washington, DC 20004, USA.
  • Long CA; Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.
  • Miura K; Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.
  • Ashfield R; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK; Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, OX1 3QU Oxford, UK; The Jenner Institute, University of Oxford, Old Road Campus Research Buildi
  • Skinner K; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK; Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, OX1 3QU Oxford, UK; The Jenner Institute, University of Oxford, Old Road Campus Research Buildi
  • Howarth MR; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK.
  • Biswas S; The Jenner Institute, University of Oxford, Old Road Campus Research Building, OX3 7DQ Oxford, UK.
  • Draper SJ; Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, OX1 3QU Oxford, UK; Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, OX1 3QU Oxford, UK; The Jenner Institute, University of Oxford, Old Road Campus Research Buildi
Cell Rep Med ; 5(7): 101654, 2024 Jul 16.
Article em En | MEDLINE | ID: mdl-39019011
ABSTRACT
Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) is a leading blood-stage malaria vaccine antigen target, currently in a phase 2b clinical trial as a full-length soluble protein/adjuvant vaccine candidate called RH5.1/Matrix-M. We identify that disordered regions of the full-length RH5 molecule induce non-growth inhibitory antibodies in human vaccinees and that a re-engineered and stabilized immunogen (including just the alpha-helical core of RH5) induces a qualitatively superior growth inhibitory antibody response in rats vaccinated with this protein formulated in Matrix-M adjuvant. In parallel, bioconjugation of this immunogen, termed "RH5.2," to hepatitis B surface antigen virus-like particles (VLPs) using the "plug-and-display" SpyTag-SpyCatcher platform technology also enables superior quantitative antibody immunogenicity over soluble protein/adjuvant in vaccinated mice and rats. These studies identify a blood-stage malaria vaccine candidate that may improve upon the current leading soluble protein vaccine candidate RH5.1/Matrix-M. The RH5.2-VLP/Matrix-M vaccine candidate is now under evaluation in phase 1a/b clinical trials.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Plasmodium falciparum / Anticorpos Antiprotozoários / Proteínas de Protozoários / Vacinas Antimaláricas / Vacinas de Partículas Semelhantes a Vírus Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Plasmodium falciparum / Anticorpos Antiprotozoários / Proteínas de Protozoários / Vacinas Antimaláricas / Vacinas de Partículas Semelhantes a Vírus Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article